Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2001 Oct-Dec;5(4):378-87.
doi: 10.1111/j.1582-4934.2001.tb00172.x.

Statins: mechanism of action and effects

Affiliations
Review

Statins: mechanism of action and effects

C Stancu et al. J Cell Mol Med. 2001 Oct-Dec.

Abstract

The beneficial effects of statins are the result of their capacity to reduce cholesterol biosyntesis, mainly in the liver, where they are selectively distributed, as well as to the modulation of lipid metabolism, derived from their effect of inhibition upon HMG-CoA reductase. Statins have antiatherosclerotic effects, that positively correlate with the percent decrease in LDL cholesterol. In addition, they can exert antiatherosclerotic effects independently of their hypolipidemic action. Because the mevalonate metabolism generates a series of isoprenoids vital for different cellular functions, from cholesterol synthesis to the control of cell growth and differentiation, HMG-CoA reductase inhibition has beneficial pleiotropic effects. Consequently, statins reduce significantly the incidence of coronary events, both in primary and secondary prevention, being the most efficient hypolipidemic compounds that have reduced the rate of mortality in coronary patients. Independent of their hypolipidemic properties, statins interfere with events involved in bone formation and impede tumor cell growth.

PubMed Disclaimer

References

    1. Vaughan C.J., Gotto A.M., Basson C.T., The evolving role of statins in the management of atherosclerosis, J. Am. Coll. Cardiol., 35: 1–10, 2000. - PubMed
    1. Hunninghake D.B., HMG‐CoA reductase inhibitors, Curr. Opin. Lipidol., 3: 22–8, 1992. - PubMed
    1. Bellosta S., Ferri N., Bernini F., Paoletti R., Corsini A., Non‐lipid‐related effects of statins, Ann. Med., 32: 164–176, 2000. - PubMed
    1. Meier C.R., Schlienger R.G., Kraenzlin M.E., Schlegel B., Jick H., HMG‐CoA reductase inhibitors and the risk of fractures, JAMA, 283: 3205–3210, 2000. - PubMed
    1. Blum C.B., Comparison of properties of four inhibitors of 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase, Am. J. Cardiol., 73: 3D–11D, 1994. - PubMed

MeSH terms

Substances